MedWell Laboratories
Anti-Inflammatory Drugs to Manage Chronic Inflammation
Non Active, Dec 2016
Company Overview
Snapshot
Founded in January 2009 by Taher Nassar, MedWell Laboratories operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of anti-inflammatory drugs.
Business overview
MedWell Laboratories is a pharmaceutical company developing a novel approach to managing mild to moderate chronic inflammatory disorders. The company's core technology involves anti-inflammatory drugs based on natural fatty acids and amino acids, designed to act as selective inhibitors of both COX-2 and 5-LOX enzymes. MedWell Laboratories targets the global pharmaceutical market, specifically within the Health Tech & Life Sciences sector, focusing on drugs discovery and development.
Company Intelligence Q&A
- What is MedWell Laboratories' primary focus?
- MedWell Laboratories focuses on developing anti-inflammatory drugs to manage mild to moderate chronic inflammatory disorders, offering an alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs).
- What is the core technology behind MedWell Laboratories' drugs?
- The company's drugs are based on proprietary technology utilizing natural fatty acids and amino acids. These compounds are designed to reduce inflammation by selectively inhibiting both COX-2 and 5-LOX enzymes.
- Who founded MedWell Laboratories?
- MedWell Laboratories was co-founded by Taher Nassar in January 2009.
- In which sector does MedWell Laboratories primarily operate?
- MedWell Laboratories operates within the Pharmaceuticals sector, specifically focusing on Health Tech & Life Sciences, and Drugs Discovery & Development.
- What is the current product development stage for MedWell Laboratories?
- MedWell Laboratories is currently in the R&D stage for its product development, focusing on anti-inflammatory drugs based on natural fatty acids and amino acids.